CN104478865B - 用于治疗例如癌症的疾病的取代的嘧啶 - Google Patents
用于治疗例如癌症的疾病的取代的嘧啶 Download PDFInfo
- Publication number
- CN104478865B CN104478865B CN201410635154.8A CN201410635154A CN104478865B CN 104478865 B CN104478865 B CN 104478865B CN 201410635154 A CN201410635154 A CN 201410635154A CN 104478865 B CN104478865 B CN 104478865B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- group
- cycloalkyl
- compound
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)(*=[N+][O-])c1cccc(OC)c1 Chemical compound CC(C)(*=[N+][O-])c1cccc(OC)c1 0.000 description 1
- AJBGTOYTKPVUPX-UHFFFAOYSA-N CC(C)(C(O)=O)c1cccc(OC)c1 Chemical compound CC(C)(C(O)=O)c1cccc(OC)c1 AJBGTOYTKPVUPX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (12)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08169807.8 | 2008-11-24 | ||
EP08169807 | 2008-11-24 | ||
EP09169654.2 | 2009-09-07 | ||
EP09169654 | 2009-09-07 | ||
CN200980155031.1A CN102292322B (zh) | 2008-11-24 | 2009-11-24 | 用于治疗例如癌症的疾病的取代的嘧啶 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980155031.1A Division CN102292322B (zh) | 2008-11-24 | 2009-11-24 | 用于治疗例如癌症的疾病的取代的嘧啶 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104478865A CN104478865A (zh) | 2015-04-01 |
CN104478865B true CN104478865B (zh) | 2017-09-22 |
Family
ID=42115425
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410635154.8A Active CN104478865B (zh) | 2008-11-24 | 2009-11-24 | 用于治疗例如癌症的疾病的取代的嘧啶 |
CN200980155031.1A Active CN102292322B (zh) | 2008-11-24 | 2009-11-24 | 用于治疗例如癌症的疾病的取代的嘧啶 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980155031.1A Active CN102292322B (zh) | 2008-11-24 | 2009-11-24 | 用于治疗例如癌症的疾病的取代的嘧啶 |
Country Status (27)
Country | Link |
---|---|
US (4) | US8846689B2 (zh) |
EP (1) | EP2367800B9 (zh) |
JP (1) | JP5622740B2 (zh) |
KR (1) | KR101710058B1 (zh) |
CN (2) | CN104478865B (zh) |
AP (1) | AP2960A (zh) |
AR (1) | AR074210A1 (zh) |
AU (1) | AU2009317170B2 (zh) |
BR (1) | BRPI0922801B1 (zh) |
CA (1) | CA2744351C (zh) |
CL (1) | CL2011001215A1 (zh) |
CO (1) | CO6511283A2 (zh) |
EA (1) | EA021997B1 (zh) |
EC (1) | ECSP11011079A (zh) |
ES (1) | ES2664499T3 (zh) |
GE (1) | GEP20146072B (zh) |
HK (1) | HK1160841A1 (zh) |
IL (1) | IL212814B (zh) |
MA (1) | MA32811B1 (zh) |
MX (1) | MX337116B (zh) |
MY (1) | MY176944A (zh) |
NZ (1) | NZ592925A (zh) |
PE (1) | PE20120034A1 (zh) |
TN (1) | TN2011000259A1 (zh) |
TW (1) | TWI491605B (zh) |
UY (1) | UY32259A (zh) |
WO (1) | WO2010058032A2 (zh) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR074209A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina utiles para el tratamiento del cancer |
AR074210A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
WO2011018517A1 (en) | 2009-08-14 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
AU2012216893B2 (en) * | 2011-02-17 | 2016-08-11 | Cancer Therapeutics Crc Pty Limited | FAK inhibitors |
ES2724525T3 (es) * | 2011-02-17 | 2019-09-11 | Cancer Therapeutics Crc Pty Ltd | Inhibidores selectivos de FAK |
EP2832734A4 (en) * | 2012-03-28 | 2015-08-26 | Takeda Pharmaceutical | HETEROCYCLIC CONNECTION |
CN105530923B (zh) * | 2013-09-09 | 2019-07-23 | 佩洛通治疗公司 | 芳基醚及其用途 |
WO2016145045A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions for use in treating glioblastoma |
EP3268362B1 (en) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
WO2016144825A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
EP3267792A4 (en) | 2015-03-11 | 2018-09-26 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
WO2016168510A1 (en) | 2015-04-17 | 2016-10-20 | Peloton Therapeutics, Inc. | Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
US20170066778A1 (en) | 2015-09-04 | 2017-03-09 | Aunova Medchem LLC | Solubility for target compounds |
AU2020388848A1 (en) | 2019-11-18 | 2022-05-26 | Inxmed (Nanjing) Co., Ltd. | Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation |
CA3159860A1 (en) * | 2019-11-28 | 2021-06-03 | Zaiqi Wang | Use of bi853520 in cancer treatment |
MX2022009612A (es) | 2020-02-05 | 2022-09-19 | Inxmed Nanjing Co Ltd | Combinacion de bi853520 con farmacos quimioterapeuticos. |
TW202206425A (zh) * | 2020-08-03 | 2022-02-16 | 大陸商應世生物科技(南京)有限公司 | 化合物的固體形式 |
WO2023020291A1 (zh) * | 2021-08-16 | 2023-02-23 | 应世生物科技(南京)有限公司 | In10018与pld的联用 |
AU2022422848A1 (en) | 2021-12-21 | 2024-06-13 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Compound as fak inhibitor and use thereof |
WO2023160614A1 (zh) * | 2022-02-28 | 2023-08-31 | 微境生物医药科技(上海)有限公司 | 作为fak抑制剂的化合物及其用途 |
TW202408528A (zh) * | 2022-06-24 | 2024-03-01 | 大陸商應世生物科技(南京)有限公司 | 治療腫瘤的藥物組合及用途 |
CN117462553A (zh) * | 2022-07-20 | 2024-01-30 | 益方生物科技(上海)股份有限公司 | 药物组合产品以及组合疗法 |
WO2024041527A1 (zh) * | 2022-08-24 | 2024-02-29 | 应世生物科技(南京)有限公司 | Fak抑制剂及微管抑制剂的药物组合及用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1406230A (zh) * | 2000-03-01 | 2003-03-26 | 阿斯特拉曾尼卡有限公司 | 用作抗肿瘤药的2,4-二(杂-)芳基氨基(-氧基)-5-取代的嘧啶 |
CN101006079A (zh) * | 2004-08-27 | 2007-07-25 | 诺瓦提斯公司 | 嘧啶衍生物 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
ES2274634T3 (es) | 1998-08-29 | 2007-05-16 | Astrazeneca Ab | Compuestos de pirimidina. |
US6906067B2 (en) * | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004886D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
PT1438053E (pt) | 2001-10-17 | 2008-09-25 | Boehringer Ingelheim Int | Derivados de pirimidina, medicamento contendo estes compostos, sua utilização e processo para a sua preparação |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
CN1717396A (zh) | 2002-11-28 | 2006-01-04 | 舍林股份公司 | Chk-、Pdk-和Akt-抑制嘧啶,其制备及作为药物的用途 |
CL2004000303A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
WO2004074244A2 (en) | 2003-02-20 | 2004-09-02 | Smithkline Beecham Corporation | Pyrimidine compounds |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
US7504396B2 (en) * | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
WO2005016894A1 (en) | 2003-08-15 | 2005-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
US7521457B2 (en) * | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
ES2371924T3 (es) | 2004-09-30 | 2012-01-11 | Tibotec Pharmaceuticals | Pirimidinas 5-carbo o heterociclo- sustituidas que inhiben el hiv. |
AU2006204752A1 (en) | 2005-01-14 | 2006-07-20 | Neurogen Corporation | Heteroaryl substituted quinolin-4-ylamine analogues |
US20070032514A1 (en) | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
US20090149467A1 (en) | 2005-09-15 | 2009-06-11 | Merck & Co., Inc. | Tyrosine Kinase Inhibitors |
US20080318989A1 (en) * | 2005-12-19 | 2008-12-25 | Burdick Daniel J | Pyrimidine Kinase Inhibitors |
FR2896503B1 (fr) * | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
TW200804364A (en) | 2006-02-22 | 2008-01-16 | Boehringer Ingelheim Int | New compounds |
TWI400234B (zh) | 2006-03-31 | 2013-07-01 | Janssen Pharmaceutica Nv | 作為組織胺h4受體調節劑之苯并咪唑-2-基嘧啶類及吡類 |
GB0619343D0 (en) | 2006-09-30 | 2006-11-08 | Vernalis R&D Ltd | New chemical compounds |
WO2008040951A1 (en) | 2006-10-03 | 2008-04-10 | Astrazeneca Ab | Compounds |
KR101475091B1 (ko) | 2006-12-13 | 2014-12-22 | 에프. 호프만-라 로슈 아게 | 비뉴클레오시드 역전사 효소 억제제로서 2-(피페리딘-4-일)-4-페녹시- 또는 페닐아미노-피리미딘 유도체 |
CA2670645A1 (en) * | 2006-12-19 | 2008-07-03 | Genentech, Inc. | Pyrimidine kinase inhibitors |
CA2702647C (en) * | 2007-01-31 | 2016-03-22 | Ym Biosciences Australia Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
ES2465673T3 (es) * | 2007-04-16 | 2014-06-06 | Hutchison Medipharma Enterprises Limited | Derivados de pirimidina |
WO2009115583A1 (en) | 2008-03-20 | 2009-09-24 | Boehringer Ingelheim International Gmbh | Regioselective preparation of substituted pyrimidines |
KR101955914B1 (ko) | 2008-06-27 | 2019-03-11 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
AR074210A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
AR074209A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina utiles para el tratamiento del cancer |
CN102482277B (zh) | 2009-05-05 | 2017-09-19 | 达纳-法伯癌症研究所有限公司 | 表皮生长因子受体抑制剂及治疗障碍的方法 |
-
2009
- 2009-11-23 AR ARP090104511A patent/AR074210A1/es not_active Application Discontinuation
- 2009-11-23 TW TW098139766A patent/TWI491605B/zh active
- 2009-11-24 CN CN201410635154.8A patent/CN104478865B/zh active Active
- 2009-11-24 JP JP2011536901A patent/JP5622740B2/ja active Active
- 2009-11-24 MY MYPI2011002290A patent/MY176944A/en unknown
- 2009-11-24 EP EP09756513.9A patent/EP2367800B9/en active Active
- 2009-11-24 KR KR1020117014264A patent/KR101710058B1/ko active IP Right Grant
- 2009-11-24 NZ NZ592925A patent/NZ592925A/xx unknown
- 2009-11-24 UY UY0001032259A patent/UY32259A/es not_active Application Discontinuation
- 2009-11-24 AU AU2009317170A patent/AU2009317170B2/en active Active
- 2009-11-24 MX MX2011005420A patent/MX337116B/es active IP Right Grant
- 2009-11-24 BR BRPI0922801-2A patent/BRPI0922801B1/pt active IP Right Grant
- 2009-11-24 EA EA201100794A patent/EA021997B1/ru not_active IP Right Cessation
- 2009-11-24 GE GEAP200912270A patent/GEP20146072B/en unknown
- 2009-11-24 PE PE2011001080A patent/PE20120034A1/es active IP Right Grant
- 2009-11-24 US US13/130,669 patent/US8846689B2/en active Active
- 2009-11-24 AP AP2011005706A patent/AP2960A/xx active
- 2009-11-24 ES ES09756513.9T patent/ES2664499T3/es active Active
- 2009-11-24 CA CA2744351A patent/CA2744351C/en active Active
- 2009-11-24 CN CN200980155031.1A patent/CN102292322B/zh active Active
- 2009-11-24 WO PCT/EP2009/065768 patent/WO2010058032A2/en active Application Filing
-
2011
- 2011-05-11 IL IL212814A patent/IL212814B/en active IP Right Grant
- 2011-05-20 MA MA33866A patent/MA32811B1/fr unknown
- 2011-05-20 TN TN2011000259A patent/TN2011000259A1/fr unknown
- 2011-05-24 EC EC2011011079A patent/ECSP11011079A/es unknown
- 2011-05-24 CO CO11063881A patent/CO6511283A2/es not_active Application Discontinuation
- 2011-05-24 CL CL2011001215A patent/CL2011001215A1/es unknown
-
2012
- 2012-02-07 HK HK12101136.9A patent/HK1160841A1/zh unknown
-
2014
- 2014-08-29 US US14/472,627 patent/US20140371205A1/en not_active Abandoned
-
2015
- 2015-09-04 US US14/845,529 patent/US20150376141A1/en not_active Abandoned
-
2016
- 2016-08-24 US US15/245,854 patent/US9676762B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1406230A (zh) * | 2000-03-01 | 2003-03-26 | 阿斯特拉曾尼卡有限公司 | 用作抗肿瘤药的2,4-二(杂-)芳基氨基(-氧基)-5-取代的嘧啶 |
CN101006079A (zh) * | 2004-08-27 | 2007-07-25 | 诺瓦提斯公司 | 嘧啶衍生物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104478865B (zh) | 用于治疗例如癌症的疾病的取代的嘧啶 | |
CN102695700A (zh) | 用作蛋白酪氨酸激酶2抑制剂的嘧啶衍生物 | |
EP1902037B1 (de) | 2,4-diamino-pyrimidine als aurora inhibitoren | |
EP2027107B1 (de) | 2, 4 -diamino pyrimidine als inhibitoren von zellzykluskinasen | |
EP1989198B1 (de) | 2, 4-diaminopyrimidinderivate zur behandlung und/oder prävention von krebs, infektionen, entzündungs- und autoimmunerkrankungen | |
EP1751118B1 (de) | Pyrimidine als plk inhibitoren | |
CA2865467C (en) | 6-alkynyl pyridines as smac mimetics | |
CN102448943A (zh) | 用于治疗特征在于过度或异常细胞增殖的疾病的2,4-二氨基嘧啶 | |
CN102421762A (zh) | 用于治疗癌症的取代的嘧啶 | |
EP2041132A2 (en) | New compounds | |
US7981880B2 (en) | 3-(aminomethyliden) 2-indolinone derivates and their use as cell proliferation inhibitors | |
WO2007115999A1 (en) | 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer | |
EP1896472A1 (de) | Alpha-carboline als cdk-1 inhibitoren | |
CN102112468A (zh) | 新化合物 | |
CN102459224A (zh) | 5-炔基-吡啶 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: In Germany Applicant after: BOEHRINGER INGELHEIM INTERNATIONAL GmbH Address before: In Germany Applicant before: Boehringer Ingelheim International GmbH |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 902, 9 / F, Chinachem building, 34-37 Connaught Road Central, Hong Kong, China Patentee after: Yingshi Biology (Hong Kong) Co.,Ltd. Address before: 902, 9 / F, Chinachem building, 34-37 Connaught Road Central, Hong Kong, China Patentee before: Jianqiao Pharmaceutical (Hong Kong) Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210902 Address after: 902, 9 / F, Chinachem building, 34-37 Connaught Road Central, Hong Kong, China Patentee after: Jianqiao Pharmaceutical (Hong Kong) Co.,Ltd. Address before: Germany Patentee before: BOEHRINGER INGELHEIM INTERNATIONAL GmbH |